These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 18059501)

  • 1. The application of quantitative methods for identifying and exploring the presence of bias in systematic reviews: PDE-5 inhibitors for erectile dysfunction.
    Bekkering GE; Abou-Setta AM; Kleijnen J
    Int J Impot Res; 2008; 20(3):264-77. PubMed ID: 18059501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
    Doggrell S
    Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effectiveness and patient satisfaction after 6 months of treatment with tadalafil, sildenafil, and vardenafil: results from the erectile dysfunction observational study (EDOS).
    Martin-Morales A; Haro JM; Beardsworth A; Bertsch J; Kontodimas S;
    Eur Urol; 2007 Feb; 51(2):541-50; discussion 550. PubMed ID: 17084518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of erectile dysfunction after radical retropubic prostatectomy with PDE5 inhibitor].
    Jin W; Huang YR
    Zhonghua Nan Ke Xue; 2005 Sep; 11(9):708-12. PubMed ID: 16209216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phosphodiesterase inhibitors: effectiveness and new applications].
    van Driel MF
    Ned Tijdschr Geneeskd; 2006 Jul; 150(29):1613-6. PubMed ID: 16901064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations.
    Berner MM; Kriston L; Harms A
    Int J Impot Res; 2006; 18(3):229-35. PubMed ID: 16239897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of vardenafil in difficult-to-treat erectile dysfunction men].
    Wang CH
    Zhonghua Nan Ke Xue; 2006 Apr; 12(4):377-80. PubMed ID: 16683577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PDE-5 inhibitors: current status and future trends.
    Masson P; Lambert SM; Brown M; Shabsigh R
    Urol Clin North Am; 2005 Nov; 32(4):511-25, viii. PubMed ID: 16291042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK.
    Kell PD; Hvidsten K; Morant SV; Harnett JP; Bridge S
    BJU Int; 2007 Apr; 99(4):860-3. PubMed ID: 17378846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vardenafil rescue rates of sildenafil nonresponders: objective assessment of 327 patients with erectile dysfunction.
    Brisson TE; Broderick GA; Thiel DD; Heckman MG; Pinkstaff DM
    Urology; 2006 Aug; 68(2):397-401. PubMed ID: 16904460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of phosphodiesterase-5 inhibitors by college students.
    Freitas VM; Menezes FG; Antonialli MM; Nascimento JW
    Rev Saude Publica; 2008 Oct; 42(5):965-7. PubMed ID: 18797570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors.
    Taylor J; Baldo OB; Storey A; Cartledge J; Eardley I
    BJU Int; 2009 May; 103(10):1392-5. PubMed ID: 19154494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of sildenafil citrate (Viagra) and tadalafil (Cialis) on sexual responses in Saudi men with erectile dysfunction in routine clinical practice.
    Ali ST
    Pak J Pharm Sci; 2008 Jul; 21(3):275-81. PubMed ID: 18614424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Benefits of tadalafil in sexual activity-related time concerns].
    Yuang RQ
    Zhonghua Nan Ke Xue; 2010 Jun; 16(6):572-5. PubMed ID: 20608366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil.
    Ahn TY; Lee SW; Kim SW; Yang DY; Park NC; Min KS; Park K; Paick JS; Dyachkova Y; Dwight T; Lee MS
    Asian J Androl; 2007 Nov; 9(6):760-70. PubMed ID: 17968461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-possession of phosphodiesterase type-5 inhibitors (PDE5-I) with nitrates.
    Chang LL; Ma M; Allmen Hv; Henderson SC; Harper K; Hornbuckle K
    Curr Med Res Opin; 2010 Jun; 26(6):1451-9. PubMed ID: 20394470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
    Shabsigh R; Seftel AD; Rosen RC; Porst H; Ahuja S; Deeley MC; Garcia CS; Giuliano F
    Urology; 2006 Oct; 68(4):689-96. PubMed ID: 17070333
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of formulary replacement of sildenafil by vardenafil at a local VA hospital.
    Singh M; Seftel AD
    Int J Impot Res; 2008; 20(2):188-91. PubMed ID: 17805337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tadalafil (Cialis) for men with erectile dysfunction.
    Eardley I; Cartledge J
    Int J Clin Pract; 2002 May; 56(4):300-4. PubMed ID: 12074215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.